Morning Overview on MSN
A year of added prostate-cancer therapy cut the odds the disease spreads, a major trial found
Men treated for prostate cancer after surgery now have clearer evidence that extending hormone therapy from six months to two ...
An AI-powered biomarker based on histology alone predicted survival among men with metastatic hormone-sensitive prostate cancer and identified those who benefitted from escalation to triplet therapy.
In the United States, prostate cancer is a leading cause of cancer-related disease and death in men. About half of prostate ...
Blue Earth Therapeutics, a clinical-stage radiopharmaceutical company and University College London (UCL) today announced ...
Hormone patches are as good at controlling locally advanced prostate cancer as the injections typically used to deliver hormone therapy, according to the results of a large clinical trial led by UCL ...
PET scan changed treatment plans for nearly half of patients whose first scan was negative, according to new research ...
Prostate cancer relapse treatment could be cut from 35 visits to just five. See how new radiation technology may change your ...
NeoGenomics launched PTEN IHC CDx, the first IHC companion diagnostic test approved by the U.S. FDA for patients with ...
Gadget Review on MSN
Cornell's silica nanoparticles wiped out prostate cancer in mice
Cornell silica nanoparticles eliminated prostate tumors in mice by triggering ferroptosis and activating immune response, ...
Researchers found that the common blood pressure drug telmisartan can significantly improve the performance of the cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results